TY - JOUR
KW - Adult
KW - Aged
KW - Biomarkers
KW - Brain-Derived Neurotrophic Factor
KW - Case-Control Studies
KW - Drug Therapy, Combination
KW - Female
KW - Humans
KW - Leprostatic Agents
KW - leprosy
KW - Male
KW - Middle Aged
AU - Costa RD
AU - Mendonça VA
AU - Penido RA
AU - Lyon S
AU - Costa AMDD
AU - Costa MD
AU - Terra FS
AU - Bretas TL
AU - Antunes CMF
AU - Teixeira AL
AB - <p>Brain-derived neurotrophic factor (BDNF) is a neurotrophin involved in the survival of neurons and growth and differentiation of dendrites and axons. The purpose of the present study was to evaluate plasma levels of BDNF of leprosy patients at different stages of multidrug therapy (MDT) in comparison with non-infected individuals. Plasma levels of BDNF were measured by ELISA in 30 healthy controls and 37 leprosy patients at diagnosis, during and after MDT. Plasma levels of BDNF tended to be higher in control subjects in comparison with leprosy patients, but this difference does not reach statistical significance. Interestingly, BDNF levels changed following MDT, achieving statistical difference only at the 2(nd) dose of MDT. These results indicate that BDNF may not be a surrogate marker of leprosy infection and/or related neuropathy. Further research is needed to investigate the meaning of BDNF level changes following leprosy treatment.</p>
BT - Arquivos de neuro-psiquiatria
C1 - http://www.ncbi.nlm.nih.gov/pubmed/21359431?dopt=Abstract
DA - 2011 Feb
DO - 10.1590/s0004-282x2011000100019
IS - 1
J2 - Arq Neuropsiquiatr
LA - eng
N2 - <p>Brain-derived neurotrophic factor (BDNF) is a neurotrophin involved in the survival of neurons and growth and differentiation of dendrites and axons. The purpose of the present study was to evaluate plasma levels of BDNF of leprosy patients at different stages of multidrug therapy (MDT) in comparison with non-infected individuals. Plasma levels of BDNF were measured by ELISA in 30 healthy controls and 37 leprosy patients at diagnosis, during and after MDT. Plasma levels of BDNF tended to be higher in control subjects in comparison with leprosy patients, but this difference does not reach statistical significance. Interestingly, BDNF levels changed following MDT, achieving statistical difference only at the 2(nd) dose of MDT. These results indicate that BDNF may not be a surrogate marker of leprosy infection and/or related neuropathy. Further research is needed to investigate the meaning of BDNF level changes following leprosy treatment.</p>
PY - 2011
SP - 100
EP - 4
T2 - Arquivos de neuro-psiquiatria
TI - Study of the profile of the neurotrophin BDNF in new leprosy cases before, during and after multidrug therapy.
UR - http://www.scielo.br/pdf/anp/v69n1/19.pdf
VL - 69
SN - 1678-4227
ER -